Prognostic relevance of high expression of kynurenine pathway markers in glioblastoma
Open Access
- 28 June 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-8
Abstract
Glioblastoma (GBM) continues to exhibit a discouraging survival rate despite extensive research into new treatments. One factor contributing to its poor prognosis is the tumor's immunosuppressive microenvironment, in which the kynurenine pathway (KP) plays a significant role. This study aimed to explore how KP impacts the survival of newly diagnosed GBM patients. We examined tissue samples from 108 GBM patients to assess the expression levels of key KP markers—tryptophan 2,3-dioxygenase (TDO2), indoleamine 2,3-dioxygenase (IDO1/2), and the aryl hydrocarbon receptor (AhR). Using immunohistochemistry and QuPath software, three tumor cores were analyzed per patient to evaluate KP marker expression. Kaplan–Meier survival analysis and stepwise multivariate Cox regression were used to determine the effect of these markers on patient survival. Results showed that patients with high expression of TDO2, IDO1/2, and AhR had significantly shorter survival times. This finding held true even when controlling for other known prognostic variables, with a hazard ratio of 3.393 for IDO1, 2.775 for IDO2, 1.891 for TDO2, and 1.902 for AhR. We suggest that KP markers could serve as useful tools for patient stratification, potentially guiding future immunomodulating trials and personalized treatment approaches for GBM patients.Keywords
This publication has 35 references indexed in Scilit:
- Tryptophan metabolism in brain tumors — IDO and beyondCurrent Opinion in Immunology, 2021
- Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolutionFrontiers of Medicine, 2021
- Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathwaySignal Transduction and Targeted Therapy, 2020
- Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39Nature Neuroscience, 2019
- Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumorsJournal of Neuro-Oncology, 2018
- QuPath: Open source software for digital pathology image analysisScientific Reports, 2017
- Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathwayGlia, 2014
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptorNature, 2011
- Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptorNature, 2008
- Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brainJournal of Neural Transmission, 2006